COLORADO SPRINGS, Colo., Jan. 29, 2014 /PRNewswire/ -- (NASDAQ OTC: CBIS) After President Obama's State of the Union Address this week, Cannabis Science is leading the private sector effort to take cannabis-derived drugs to market. The company's government relations team lead, Rick Blake, is working with the U.S. House of Representatives' Cannabis Caucus to ensure that the President signs an Executive Order to decriminalize cannabis research. This is one of the bipartisan initiatives of the Members of the Cannabis Caucus being facilitated by Cannabis Science. In contrast to many other countries, the regulatory landscape of the United States creates unreasonable restrictions on the ability of scientists and physicians to explore promising patient-driven research involving cannabis and cannabinoids.
"Thousands of patients are awaiting the President's action to set cannabis research free," said Dorothy Bray, Ph.D., Director and CEO of Cannabis Science, Inc., one of the leading supporters of scientific cannabis drug development in the private sector. We applaud those congressional members in Colorado, California, Oregon, New York, Massachusetts and many other jurisdictions in the United States who have determined to take forward U.S. cannabis drug research." Dr. Bray and others on the CBIS team support critical legislation for the use of cannabis in the treatment of multiple illnesses including cancer.
Cannabis Science also supports legislation to expand funding for small biotechnology firms, as they are often the most innovative in taking new drugs to market. "We call on the President and the Congress to invest $3.5 billion into new drug development through funding for innovative small biotechnology firms," said Dr. Robert A. Melamede, Ph.D., President of Cannabis Science. As multiple countries openly welcome research into cannabis based healthcare products, Cannabis Science believes that the U.S. should not allow other nations to wrest the lead from American small biotechnology firms. Development in the cannabis sector will foster efficacious therapies to thousands of patients with a wide range of illnesses and diseases. In this regard, Cannabis Science supports the efforts of a coalition of advocacy groups, including the Marijuana Policy Project, Patients Out of Time, Americans for Safe Access, and NORML, among others.
Cannabis Science is preparing to initiate observational clinical studies and entering pharmaceutical development of its proprietary products.
About Cannabis Science, Inc.
Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. The Company's initial pharmaceutical focus is on skin cancers and neurological conditions.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Government Relations Inquiries
Rick Blake, Government Affairs Representative
Robert Kane, Director & CFO
SOURCE Cannabis Science, Inc.